Volume 7 Issue 3
May  2016
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2016  >  7(3): 222-226
Wang Yue, Zhu Zhijun, Sun Liying, et al. Comparison of clinical efficacy between tauroursodeoxycholic acid and ursodesoxycholic acid on liver function recovery after liver transplantation[J]. ORGAN TRANSPLANTATION, 2016, 7(3): 222-226. doi: 10.3969/j.issn.1674-7445.2016.03.013
Citation: Wang Yue, Zhu Zhijun, Sun Liying, et al. Comparison of clinical efficacy between tauroursodeoxycholic acid and ursodesoxycholic acid on liver function recovery after liver transplantation[J]. ORGAN TRANSPLANTATION, 2016, 7(3): 222-226. doi: 10.3969/j.issn.1674-7445.2016.03.013
shu

Comparison of clinical efficacy between tauroursodeoxycholic acid and ursodesoxycholic acid on liver function recovery after liver transplantation

doi: 10.3969/j.issn.1674-7445.2016.03.013

  • Tianjin Medical University, Tianjin 300070, China

More Information
  • Corresponding author: Zhu Zhijun, Email: zhu-zhijun@outlook.com
  • Received Date: 2016-01-20
    Available Online: 2021-01-19
  • Publish Date: 2016-05-15
    Abstract
  •   Objective  To compare the clinical efficacy between tauroursodeoxycholic acid and ursodesoxycholic acid on liver function recovery following liver transplantation.  Methods  Twenty eight recipients undergoing orthotopic liver transplantation in Beijing Friendship Hospital Affiliated to Capital Medical University from 2006 to 2012 were recruited in this investigation. All patients were orally administered with ursodesoxycholic acid for 3 months and subsequently received oral administration of tauroursodeoxycholic acid for 6 months. The changes in the levels of total bile acid (TBA), total bilirubin (TB), direct bilirubin (DB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyl transpeptidase (GGT) were statistically compared before and 1, 2, 3, 4, 5, 6 and 9 months after enrollment. At 3 and 9 months following enrollment, the components of bile acid were determined in 5 cases to compare the changes between the hydrophobic and hydrophilic bile acid.  Results  Within 3 months after oral administration of ursodesoxycholic acid, all parameters related to liver function were elevated. Compared with the level at 3 months after enrollment, the level of TBA was significantly decreased at 5 and 9 months after enrollment. The level of ALT declined at 5 and 6 months. The concentration of AST was decreased at 4 and 5 months. The largest decrease in the level of ALP was noted at 9 months. The content of GGT was found to decline at 6 and 9 months (all P < 0.05). After oral administration of tauroursodeoxycholic acid, a higher level of hydrophilic bile acid was detected in the patients' bile acid, dominated by tauroursodeoxycholic acid.  Conclusions  Tauroursodeoxycholic acid exerts higher clinical efficacy on promoting the secretion of bile and protecting liver function compared with ursodesoxycholic acid after liver transplantation.

     

    • FullText(HTML)
  • loading
    • References(19)
  • [1]
    周尊强, 张正筠, 王书云, 等.肝移植术后远期胆道并发症的诊断与治疗[J].器官移植, 2013, 4(6):347-349. http://www.organtranspl.com/CN/article/downloadArticleFile.do?attachType=PDF&id=8676

    Zhou ZQ, Zhang ZY, Wang SY, et al. Diagnosis and treatment for long-term biliary complications after liver transplantation[J].Organ Transplant, 2013, 4(6):347-349. http://www.organtranspl.com/CN/article/downloadArticleFile.do?attachType=PDF&id=8676
    [2]
    Palanisamy AP, Taber DJ, Sutter AG, et al. Clinical outcomes and costs associated with in-hospital biliary complications after liver transplantation: a cross-sectional analysis[J]. J Gastrointest Surg, 2015, 19(2):282-289. doi: 10.1007/s11605-014-2675-1
    [3]
    Drzymała-Czyz. S, Jończyk-Potoczna K, Lisowska A, et al. Supplementation of ursodeoxycholic acid improves fat digestion and absorption in cystic fibrosis patients with mild liver involvement[J]. Eur J Gastroenterol Hepatol, 2016, 28(6):645-649. doi: 10.1097/MEG.0000000000000593
    [4]
    王书云, 唐美华, 陈国庆, 等.肝移植后熊去氧胆酸对肝生物化学指标及胆管并发症影响的临床随机对照研究[J].中华肝脏病杂志, 2014, 22(7):529-535. http://cpfd.cnki.com.cn/Article/CPFDTOTAL-ZHYX201210002106.htm

    Wang SY, Tang MH, Chen GQ, et al. Effect of post-liver transplantation administration of ursodeoxychofic acid on serum liver tests and biliary complications:a randomized clinical trial[J]. Chin J Hepatol, 2014, 22(7):529-535. http://cpfd.cnki.com.cn/Article/CPFDTOTAL-ZHYX201210002106.htm
    [5]
    Iijima T, Hoshino J, Suwabe T, et al. Ursodeoxycholic acid for treatment of enlarged polycystic liver[J]. Ther Apher Dial, 2016, 20(1):73-78. doi: 10.1111/tap.2016.20.issue-1
    [6]
    李伟, 王枫, 吕宗舜, 等.熊去氧胆酸治疗非酒精性脂肪性肝病的系统评价[J].世界华人消化杂志, 2013, 21(23):2335-2343. doi: 10.11569/wcjd.v21.i23.2335

    Wei L, Feng W, Lyu ZS, et al. Efficacy of ursodesoxycholic acid in treatment of nonalcoholic fatty liver disease: a Meta-analysis. [J]. World Chin J Digestol, 2013, 21(23):2335-2343. doi: 10.11569/wcjd.v21.i23.2335
    [7]
    Cheung AC, Lapointe-Shaw L, Kowgier M, et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes[J]. Aliment Pharmacol Ther, 2016, 43(2):283-293. doi: 10.1111/apt.13465
    [8]
    陈建飞, 赵期康, 李晋忠, 等.牛磺熊去氧胆酸与熊去氧胆酸对预防保胆术后结石复发的临床研究[J].中国微创外科杂志, 2014, 14(4):311-313. http://www.cnki.com.cn/Article/CJFDTOTAL-ZWWK201404010.htm

    Chen JF, Zhao QK, Li JZ, et al. A comparative clinical study for the relapse of cholelithiasis after gallbladder-preserving lithotomy between tauroursodeoxycholic acid and ursodeoxycholic acid[J]. Chin J Minim Invas Surg, 2014, 14(4):311-313. http://www.cnki.com.cn/Article/CJFDTOTAL-ZWWK201404010.htm
    [9]
    Vang S, Longley K, Steer CJ, et al. The unexpected uses of urso-and tauroursodeoxycholic acid in the treatment of non-liver diseases[J]. Glob Adv Health Med, 2014, 3(3):58-69. doi: 10.7453/gahmj.2014.017
    [10]
    Kohli R, Setchell KD, Kirby M, et al. A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery[J]. Endocrinology, 2013, 154(7):2341-2351. doi: 10.1210/en.2012-2069
    [11]
    杨晓冬, 李晖, 李晓林, 等.牛磺酸熊去氧胆酸治疗慢性乙型肝炎重叠戊型肝炎感染疗效观察[J].中国基层医药, 2014, 21(15):2375-2376. http://d.wanfangdata.com.cn/Periodical/zgjcyy201415067

    Yang XD, Li H, Li XL, et al. Observation on curative effect of tauroursodeoxycholic acid in the treatment of chronic hepatitis B infection superinfected with hepatitis E infection[J]. Chin J Prim Med Pharm, 2014, 21(15):2375-2376. http://d.wanfangdata.com.cn/Periodical/zgjcyy201415067
    [12]
    周健, 刘黎, 黄丽雯, 等.牛磺熊去氧胆酸治疗非酒精性脂肪肝疗效观察[J].实用肝脏病杂志, 2014, 17(1):80-81. http://www.cnki.com.cn/Article/CJFDTOTAL-GBSY201401025.htm

    Zhou J, Liu L, Huang LW, et al. Clinical observation of tauroursodeoxycholic acid in treatment of patients with non-alcohol fatty liver[J]. J Clin Hepatol, 2014, 17(1):80-81. http://www.cnki.com.cn/Article/CJFDTOTAL-GBSY201401025.htm
    [13]
    Pan XL, Zhao L, Li L, et al. Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial[J]. J Huazhong Univ Sci Technolog Med Sci, 2013, 33(2):189-194. doi: 10.1007/s11596-013-1095-x
    [14]
    王文涛, 杨俭, 严律南, 等.熊去氧胆酸对肝移植术后受肝者肝功能异常的治疗作用[J].中华肝脏病杂志, 2012, 20(2):144-145. http://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_zhgzbzz201202017

    Wang WT, Yang J, Yan LN, et al. Ursodeoxycholic acid treatment to resolve abnormal function in liver transplant recipients[J]. Chin J Hepatol, 2012, 20(2):144-145. http://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_zhgzbzz201202017
    [15]
    Gohlke H, Schmitz B, Sommerfeld A, et al. α5 β1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes[J]. Hepatology, 2013, 57(3):1117-1129. doi: 10.1002/hep.25992
    [16]
    曹荣, 胡旭东, 柏涛, 等.熊去氧胆酸与牛磺熊去氧胆酸联合多烯磷脂酰胆碱治疗非酒精性脂肪肝的疗效比较[J].中国药房, 2013, 24(4):365-367. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGYA201304031.htm

    Cao R, Hu XD, Bai T, et al. Comparison of therapeutic efficacy of ursodesoxycholic acid or tauro-ursodesoxycholic acid combined with polyene phosphatidylcholine for non-alcohol fatty liver disease[J]. Chin Pharm, 2013, 24(4):365-367. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGYA201304031.htm
    [17]
    Lu H, Lu L, Xu ZC, et al. Tauroursodeoxycholic acid and 4-phenyl butyric acid alleviate endoplasmic reticulum stress and improve prognosis of donation after cardiac death liver transplantation in rats[J]. Hepatobiliary Pancreat Dis Int, 2014, 13(6):586-593. doi: 10.1016/S1499-3872(14)60269-1
    [18]
    李俊, 陈虹, 范铁艳, 等.肝移植后肝功能的异常[J].中国组织工程研究, 2013, 17(31): 5686-5692. http://www.cnki.com.cn/Article/CJFDTOTAL-XDKF201331021.htm

    Li J, Chen H, Fan TY, et al. Abnormal liver function after liver transplantation[J]. Clin J Tissue Eng Res, 2013, 17(31): 5686-5692. http://www.cnki.com.cn/Article/CJFDTOTAL-XDKF201331021.htm
    [19]
    Tang C, Koulajian K, Schuiki I, et al. Glucose-induced beta cell dysfunction in vivo in rats: link between oxidative stress and endoplasmic reticulum stress[J]. Diabetologia, 2012, 55(5):1366-1379. doi: 10.1007/s00125-012-2474-8
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (457) PDF downloads(17) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return